The international surgical journal with global reach

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised double-blind, phase 3 trial. Lancet 2020; 396: 1090-1100.

Published: 9th February 2021

Authors: Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R et al.

Conclusion

The addition of atezolizumab in this study that included 333 women improved pathological complete response from 41 to 58 per cent, P=0.0044. Adverse event rates were similar.

Pubmed Link